Abstract Details

Title Lamotrigine as a First-line Agent in the Management of Paroxysmal Kinesigenic Dyskinesia

Topic Movement Disorders

Presentation(s) P14 - Poster Session 14 (11:45 AM-12:45 PM)

Poster/Presentation
Number 5-002

Background Brief episodes of involuntary movement triggered by purposeful actions are characteristic of paroxysmal kinesigenic dyskinesia (PKD) and can significantly interfere with daily life. Carbamazepine and oxcarbazepine are effective at reducing episodes but have teratogenic risks and adverse effects that limit their therapeutic potential. There is minimal evidence describing alternate sodium channel blockers as first line therapies for PKD.

Objective

To report the effectiveness of lamotrigine as a first line medication for PKD.

Design/Methods A retrospective chart review of patients with PKD seen at our tertiary care centre between Jan 2013-June 2022.

Results Of eleven identified patients, two received lamotrigine as a first line medication. Lamotrigine, at a low dose, produced a complete resolution of episodes with no reported adverse effects. Both patients were on lamotrigine for >1 year.

Conclusions Lamotrigine is an effective first line alternative to carbamazepine and oxcarbazepine for PKD. It is a safer choice for females of child bearing potential and may have increased tolerability.

Authors/Disclosures
Heather Leduc-Pessah, MD, PhD PRESENTER	Dr. Leduc-Pessah has nothing to disclose.
Asif Doja, MD, FAAN	Dr. Doja has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for the CMPA. Dr. Doja has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Integra . Dr. Doja has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Connect Care .